Skip to main content

Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
HER2 antagonists
Description

In this report, we describe cohorts of patients with live birth deliveries who had an exposure to Human Epidermal Growth Factor Receptor 2 (HER2) antagonist drugs in the IBM® MarketScan® Research Databases. The study period includes data from January 1, 2010 through September 30, 2019. We distributed this request to IBM® MarketScan® Research Databases on May 7, 2021.

Deliverables (1)
Sentinel Modular Program Report: Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
January 1, 2010 - September 30, 2019
Analysis Type
Descriptive
Population / Cohort
Females 18 years of age and older
Data Sources
IBM® MarketScan® Research Databases